Medical equipment maker Opto Circuits India today said it has entered into an licensing agreement with Biosensors for its drug eluting balloon range used for treatment of cardiac diseases.
Eurocor GmbH, a group company of Opto Circuits, has entered into a licensing agreement for their drug eluting balloon (DEB) technology and the related intellectual property rights in relation to the treatment of both coronary and peripheral artery disease with Biosensors International Group, the company said.
Both agreements will involve three Biosensors-branded DEBs-- BioStream, BioPath 014 and BioPath 035, Opto Circuits said in a joint statement without giving the financial details of the agreement.
Commenting on the development, Biosensors' Cardiovascular Division President Jeffrey B Jump said: "We are delighted to have acquired a new range of leading DEBs as a result of this licensing agreement with Eurocor."
As a first step in this process, an original equipment manufacturer (OEM) agreement is being implemented, whereby Biosensors will market and sell, under its own brand, DEBs manufactured by Eurocor, the statement said.
"This agreement is further validation for Eurocor's DEB products. There is a considerable scope for global expansion within this rapidly growing sector of the interventional devices market," Eurocor GmbH COO Antonino Laudani said on the development.
